Back

Haemodynamic forces as predictors of cardiac remodelling and outcome in heart failure with reduced ejection fraction treated with sacubitril/valsartan

26 August 2022 (08:00 - 19:30)
Organised by:
Congress Presentation Part of: Heart failure pharmacotherapy - Sacubitril/valsartan Imaging ESC Professional Premium Access ESC Congress 2022

About the speaker

Photo
Doctor Alberto Giannoni

Sant'Anna School of Advanced Studies, Pisa (Italy)

7 More presentations in this session

Presentation thumbnail
Maximum dose sacubitril/valsartan in heart failure with reduced ejection fraction: does atrial fibrillation compromise the benefits?
Doctor G. Oliveira Campos (Coimbra, PT)
Abstract Slides
Presentation thumbnail
Efficacy and safety of sacubitril valsartan in heart failure compared to renin angiotensin aldosterone system inhibitors: a systematic review and meta analysis of randomised controlled trials
Professor A. Bielecka-Dabrowa (Lodz, PL)
Abstract Slides
Presentation thumbnail
Effects of sacubitril valsartan on renal function in adults with heart failure: a systematic review and meta analysis of randomised controlled trials
Professor A. Hernandez (Storrs, US)
Abstract Slides
Presentation thumbnail
Heart failure with improved ejection fraction (HFimpEF) in patients treated with sacubitril/valsartan (SV)
Assistant Professor K. Lee (Seoul, KR)
Abstract Slides
Presentation thumbnail
Comparative effectiveness of sacubitril/valsartan versus angiotensin converting enzyme inhibitors/angiotensin receptor blockers in de novo heart failure patients
Doctor H. Schwende (Basel, CH)
Abstract Slides

Access the full session

Session thumbnail
Heart failure pharmacotherapy - Sacubitril/valsartan

The Event

Event poster

ESC Congress 2022

26 August - 29 August 2022
You may be interested in
thumbnail
Congress Presentation
Heart failure
thumbnail
Congress Session
Recent advances in clinical practice guidelines: what the imager needs to know and apply - Part 2
thumbnail
Congress Presentation
All you need to know about diagnosing heart failure in adult congenital heart disease

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources